J
John S. Kauh
Researcher at Emory University
Publications - 96
Citations - 10073
John S. Kauh is an academic researcher from Emory University. The author has contributed to research in topics: Cancer & Docetaxel. The author has an hindex of 28, co-authored 95 publications receiving 8950 citations. Previous affiliations of John S. Kauh include Georgetown University.
Papers
More filters
Journal ArticleDOI
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer,Scott S. Tykodi,Scott S. Tykodi,Laura Q.M. Chow,Wen-Jen Hwu,Suzanne L. Topalian,Patrick Hwu,Charles G. Drake,Luis H. Camacho,John S. Kauh,Kunle Odunsi,Henry C. Pitot,Omid Hamid,Shailender Bhatia,Renato G. Martins,Keith D. Eaton,Shuming Chen,Theresa M. Salay,Suresh Alaparthy,Joseph F. Grosso,Alan J. Korman,Susan M. Parker,Shruti Agrawal,Stacie M. Goldberg,Drew M. Pardoll,Ashok Kumar Gupta,Jon M. Wigginton +26 more
TL;DR: Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
Journal ArticleDOI
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Tanios Bekaii-Saab,Mitch A. Phelps,Xiaobai Li,Motoyasu Saji,Laura W. Goff,John S. Kauh,Bert H. O'Neil,Stephanie M. Balsom,Catherine Balint,Ryan Liersemann,Vasily Vasko,Mark Bloomston,William L. Marsh,L. Austin Doyle,Gilian Ellison,Michael R. Grever,Matthew D. Ringel,Miguel A. Villalona-Calero +17 more
TL;DR: Selumetinib displays interesting activity and acceptable tolerability in patients with metastatic BC, and these results warrant further evaluation of selumet inib in patientswith metastaticBC.
Journal ArticleDOI
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
John L. Marshall,Naiyer Rizvi,John S. Kauh,William L. Dahut,Manuela Figuera,Min H. Kang,William D. Figg,Irving W. Wainer,Christoff Chaissang,Megan Zhaoyang Li,Michael J. Hawkins +10 more
TL;DR: Depsipeptide can be safely administered when given as a 4-hour infusion and further clinical trials are warranted.
Journal ArticleDOI
Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).
TL;DR: This study explores long‐term survival benefits of chemoembolization with doxorubicin drug eluting beads for unresectable hepatocellular carcinoma and suggests that treatment with DEB may provide safer and more effective short‐term outcomes.
Journal ArticleDOI
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
Hemchandra Mahaseth,Edith Brutcher,John S. Kauh,Natalyn Hawk,Sungjin Kim,Zhengjia Chen,David A. Kooby,Shishir K. Maithel,Jerome C. Landry,Bassel F. El-Rayes +9 more
TL;DR: Modified FOLFIRINOX has an improved safety profile with maintained efficacy in metastatic PC and has promising activity in nonmetastatic disease.